Global genotype distribution of hepatitis C viral infection among people who inject drugs

Journal of Hepatology

Volumn 65, Issue 6, 2016, Pages 1094-1103

  Robaeys, Geert ^a,b,c   Bielen, Rob ^a,b   Azar, Darush Ghezel ^a,c   Razavi, Homie ^d   Nevens, Frederik ^c  

^a DEPARTMENT OF CARDIOLOGY   (Belgium)

^b HASSELT UNIVERSITY   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d Center for Disease Analysis   (United States)

Author keywords

Genotype; Hepatitis C; People who inject drugs; PWID; Systematic review

Indexed keywords

ARTICLE; DRUG USE; EMBASE; EUROPE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INTRAVENOUS DRUG ABUSE; MEDLINE; MISCELLANEOUS NAMED GROUPS; PEOPLE WHO INJECT DRUG; POPULATION; PREVALENCE; PRIORITY JOURNAL; PSYCINFO; QUALITY CONTROL; SOUTH AMERICA; SUBSTANCE USE; SYSTEMATIC REVIEW; AFRICA; SUBSTANCE ABUSE;

AFRICA; DRUG USERS; EUROPE; GENOTYPE; HEPATITIS C; HUMANS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84994887752     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.07.042     Document Type: Article

References (107)

1. [1] Gower, E., Estes, C., Blach, S., Razavi-Shearer, K., Razavi, H., Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 61 (2014), S45–S57.
2. [2] Edlin, B.R., Carden, M.R., Injection drug users: the overlooked core of the hepatitis C epidemic. Clin Infect Dis 42 (2006), 673–676.
3. [3] Nelson, P.K., Mathers, B.M., Cowie, B., et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 378 (2011), 571–583.
4. [4] National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C 2002 (June 10–12, 2002). Gastroenterology 123 (2002), 2082–2099.
5. [5] Di Bisceglie, A.M., Natural history of hepatitis C: its impact on clinical management. Hepatology 31 (2000), 1014–1018.
6. [6] Wyles, D.L., Gutierrez, J.A., Importance of HCV genotype 1 subtypes for drug resistance and response to therapy. J Viral Hepat 21 (2014), 229–240.
7. [7] Thein, H.H., Yi, Q., Dore, G.J., Krahn, M.D., Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 48 (2008), 418–431.
8. [8] Rueger, S., Bochud, P.Y., Dufour, J.F., et al. Impact of common risk factors of fibrosis progression in chronic hepatitis C. Gut 64 (2015), 1605–1615.
9. [9] Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 62 (2015), 932–954.
10. [10] European Association for Study of Liver: EASL recommendations on treatment of hepatitis C. J Hepatol 63 (2015), 199–236.
11. [11] Montalto, G., Cervello, M., Giannitrapani, L., Dantona, F., Terranova, A., Castagnetta, L.A., Epidemiology, risk factors, and natural history of hepatocellular carcinoma. Ann N Y Acad Sci 963 (2002), 13–20.
12. [12] Cantaloube, J.F., Laperche, S., Gallian, P., Bouchardeau, F., de Lamballerie, X., de Micco, P., Analysis of the 5′ noncoding region vs. the NS5b region in genotyping hepatitis C virus isolates from blood donors in France. J Clin Microbiol 44 (2006), 2051–2056.
13. [13] Rao, H., Wei, L., Lopez-Talavera, J.C., et al. Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol 29 (2014), 545–553.
14. [14] Daw, M.A., El-Bouzedi, A., Dau, A.A., Geographic distribution of HCV genotypes in Libya and analysis of risk factors involved in their transmission. BMC Res Notes, 8, 2015, 367.
15. [15] Jacobson, I.M., McHutchison, J.G., Dusheiko, G., et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 364 (2011), 2405–2416.
16. [16] Poordad, F., McCone, J., Bacon, B.R., et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 364 (2011), 1195–1206.
17. [17] Poordad, F., Bronowicki, J.P., Gordon, S.C., et al. Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology 143 (2012), 608–618, e1–e5.
18. [18] Lok, A.S., Gardiner, D.F., Lawitz, E., et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 366 (2012), 216–224.
19. [19] Lawitz, E., Sulkowski, M.S., Ghalib, R., et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 384 (2014), 1756–1765.
20. [20] Sulkowski, M.S., Gardiner, D.F., Rodriguez-Torres, M., et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 370 (2014), 211–221.
21. [21] Afdhal, N., Zeuzem, S., Kwo, P., et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 370 (2014), 1889–1898.
22. [22] Afdhal, N., Reddy, K.R., Nelson, D.R., et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 370 (2014), 1483–1493.
23. [23] Kowdley, K.V., Gordon, S.C., Reddy, K.R., et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 370 (2014), 1879–1888.
24. [24] Feld, J.J., Kowdley, K.V., Coakley, E., et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 370 (2014), 1594–1603.
25. [25] Ferenci, P., Bernstein, D., Lalezari, J., et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 370 (2014), 1983–1992.
26. [26] Zeuzem, S., Jacobson, I.M., Baykal, T., et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 370 (2014), 1604–1614.
27. [27] Satoh, Y., Hino, K., Kato, T., et al. Molecular epidemiologic analysis of hepatitis C virus infection in injecting drug users with acute hepatitis C in Japan. J Gastroenterol Hepatol 19 (2004), 1305–1311.
28. [28] Kato, H., Maeno, Y., Seko-Nakamura, Y., et al. Identification and phylogenetic analysis of hepatitis C virus in forensic blood samples obtained from injecting drug users. Forensic Sci Int 168 (2007), 27–33.
29. [29] Chung, H., Ueda, T., Kudo, M., Changing trends in hepatitis C infection over the past 50 years in Japan. Intervirology 53 (2010), 39–43.
30. [30] Toyoda, H., Kumada, T., Takaguchi, K., Shimada, N., Tanaka, J., Changes in hepatitis C virus genotype distribution in Japan. Epidemiol Infect 142 (2014), 2624–2628.
31. [31] Responses to annual report questionnaire for 2013 and UNODC, Afghan Opiate Trafficking through the Southern Route, 2015 (Vienna, 2015).
32. [32] United Nations Office on Drugs and Crime, World Drug Report 2015 (United Nations publication, Sales No. E.15.XI.6).
33. [33] Beyrer, C., Razak, M.H., Lisam, K., Chen, J., Lui, W., Yu, X.F., Overland heroin trafficking routes and HIV-1 spread in south and south-east Asia. AIDS 14 (2000), 75–83.
34. [34] Yu, X.F., Liu, W., Chen, J., et al. Rapid dissemination of a novel B/C recombinant HIV-1 among injection drug users in southern China. AIDS 15 (2001), 523–525.
35. [35] Xia, X., Lu, L., Tee, K.K., et al. The unique HCV genotype distribution and the discovery of a novel subtype 6u among IDUs co-infected with HIV-1 in Yunnan, China. J Med Virol 80 (2008), 1142–1152.
36. [36] Pawlotsky, J.M., Tsakiris, L., Roudot-Thoraval, F., et al. Relationship between hepatitis C virus genotypes and sources of infection in patients with chronic hepatitis C. J Infect Dis 171 (1995), 1607–1610.
37. [37] Roulot, D., Bourcier, V., Grando, V., et al. Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection. J Viral Hepat 14 (2007), 460–467.
38. [38] Lyra, A.C., Ramrakhiani, S., Bacon, B.R., Di Bisceglie, A.M., Infection with hepatitis C virus genotype 4 in the United States. J Clin Gastroenterol 38 (2004), 68–71.
39. [39] Chlabicz, S., Flisiak, R., Lapinski, T.W., et al. Epidemiological features of patients infected with HCV genotype 4 in Poland: Epidemiology of HCV genotype 4 in Poland. Hepat Mon 11 (2011), 191–194.
40. [40] Chlabicz, S., Flisiak, R., Kowalczuk, O., et al. High prevalence of genotype 4 among hepatitis C virus-infected intravenous drug users in north-eastern Poland. J Med Virol 80 (2008), 615–618.
41. [41] Zhang, C., Wu, N., Liu, J., et al. HCV subtype characterization among injection drug users: implication for a crucial role of Zhenjiang in HCV transmission in China. PLoS One, 6, 2011, e16817.
42. [42] Murphy, D.G., Willems, B., Deschenes, M., Hilzenrat, N., Mousseau, R., Sabbah, S., Use of sequence analysis of the NS5B region for routine genotyping of hepatitis C virus with reference to C/E1 and 5′ untranslated region sequences. J Clin Microbiol 45 (2007), 1102–1112.
43. [43] Al Naamani, K., Al Sinani, S., Deschenes, M., Epidemiology and treatment of hepatitis C genotypes 5 and 6. Can J Gastroenterol 27 (2013), e8–e12.
44. [44] Garten, R.J., Zhang, J., Lai, S., Liu, W., Chen, J., Yu, X.F., Coinfection with HIV and hepatitis C virus among injection drug users in southern China. Clin Infect Dis 41 (2005), S18–S24.
45. [45] Mehta, S.H., Vogt, S.L., Srikrishnan, A.K., et al. Epidemiology of hepatitis C virus infection & liver disease among injection drug users (IDUs) in Chennai, India. Indian J Med Res 132 (2010), 706–714.
46. [46] Liu, J.Y., Lin, H.H., Liu, Y.C., et al. Extremely high prevalence and genetic diversity of hepatitis C virus infection among HIV-infected injection drug users in Taiwan. Clin Infect Dis 46 (2008), 1761–1768.
47. [47] Hansurabhanon, T., Jiraphongsa, C., Tunsakun, P., et al. Infection with hepatitis C virus among intravenous-drug users: prevalence, genotypes and risk-factor-associated behaviour patterns in Thailand. Ann Trop Med Parasitol 96 (2002), 615–625.
48. [48] Peng, J.S., Wang, X., Liu, M.Q., et al. Genetic variation of hepatitis C virus in a cohort of injection heroin users in Wuhan, China. Virus Res 135 (2008), 191–196.
49. [49] Chan, D.P., Lee, S.S., Lee, K.C., The effects of widespread methadone treatment on the molecular epidemiology of hepatitis C virus infection among injection drug users in Hong Kong. J Med Virol 83 (2011), 1187–1194.
50. [50] Leung, N., Chu, C., Tam, J.S., Viral hepatitis C in Hong Kong. Intervirology 49 (2006), 23–27.
51. [51] Du, H., Qi, Y., Hao, F., et al. Complex patterns of HCV epidemic in Suzhou: evidence for dual infection and HCV recombination in East China. J Clin Virol 54 (2012), 207–212.
52. [52] Tian, D., Li, L., Liu, Y., Li, H., Xu, X., Li, J., Different HCV genotype distributions of HIV-infected individuals in Henan and Guangxi, China. PLoS One, 7, 2012, e50343.
53. [53] Tan, Y., Wei, Q.H., Chen, L.J., et al. Molecular epidemiology of HCV monoinfection and HIV/HCV coinfection in injection drug users in Liuzhou, Southern China. PLoS One, 3, 2008, e3608.
54. [54] Yan, Z., Fan, K., Wang, Y., Fan, Y., Tan, Z., Deng, G., Changing pattern of clinical epidemiology on hepatitis C virus infection in southwest china. Hepat Mon 12 (2012), 196–204.
55. [55] Zhou, Y., Wang, X., Hong, G., et al. Natural intragenotypic and intergenotypic HCV recombinants are rare in southwest China even among patients with multiple exposures. J Clin Virol 49 (2010), 272–276.
56. [56] Zhang, Z., Yao, Y., Wu, W., et al. Hepatitis C virus genotype diversity among intravenous drug users in Yunnan Province, Southwestern China. PLoS One, 8, 2013, e82598.
57. [57] Lee, Y.M., Lin, H.J., Chen, Y.J., et al. Molecular epidemiology of HCV genotypes among injection drug users in Taiwan: Full-length sequences of two new subtype 6w strains and a recombinant form_2b6w. J Med Virol 82 (2010), 57–68.
58. [58] Liao, K.F., Lai, S.W., Lin, C.Y., Huang, C.H., Lin, Y.Y., Diversity of hepatitis C virus genotypes among intravenous heroin users in Taiwan. Am J Med Sci 341 (2011), 110–112.
59. [59] Hsieh, M.H., Tsai, J.J., Hsieh, M.Y., et al. Hepatitis C virus infection among injection drug users with and without human immunodeficiency virus co-infection. PLoS One, 9, 2014, e94791.
60. [60] Maan, R., van der Meer, A.J., Recent advances in managing chronic HCV infection: focus on therapy in patients with severe liver disease. F1000Res, 5, 2016.
61. [61] Freeman, J., Sallie, R., Kennedy, A., Hieu, P.T.N., Freeman, J., Jeffreys, G., et al. High sustained virological response rates using generic direct acting antiviral treatment for hepatitis C, imported into Australia. J Hepatol 64 (2016), 183–212.
62. [62] Hagan, L.M., Wolpe, P.R., Schinazi, R.F., Treatment as prevention and cure towards global eradication of hepatitis C virus. Trends Microbiol 21 (2013), 625–633.
63. [63] Walker, C.M., Grakoui, A., Hepatitis C virus: why do we need a vaccine to prevent a curable persistent infection?. Curr Opin Immunol 35 (2015), 137–143.
64. [64] Mathers, B.M., Degenhardt, L., Phillips, B., et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet 372 (2008), 1733–1745.
65. [65] Ciccozzi, M., Zehender, G., Cento, V., et al. Molecular analysis of hepatitis C virus infection in Bulgarian injecting drug users. J Med Virol 83 (2011), 1565–1570.
66. [66] Kurelac, I., Papic, N., Sakoman, S., et al. Intravenous drug users can achieve a high sustained virological response rate: experience from Croatian reference center for viral hepatitis. Hepat Mon 11 (2011), 986–992.
67. [67] Krekulová, L., Rehák, V., Strunecký, O., Nēmecek, V., Current situation and trends in the hepatitis C virus genotype distribution among injecting drug users in the Czech Republic. Epidemiol Mikrobiol Imunol 58 (2009), 84–89.
68. [68] Tallo, T., Norder, H., Tefanova, V., et al. Genetic characterization of hepatitis C virus strains in Estonia: fluctuations in the predominating subtype with time. J Med Virol 79 (2007), 374–382.
69. [69] Bouscaillou, J., Champagnat, J., Luhmann, N., et al. Hepatitis C among people who inject drugs in Tbilisi, Georgia: an urgent need for prevention and treatment. Int J Drug Policy 25 (2014), 871–878.
70. [70] Tresó, B., Takács, M., Dencs, Á., Dudás, M., Pár, A., Rusvai, E., Molecular epidemiology of hepatitis C virus genotypes and subtypes among injecting drug users in Hungary. Euro Surveill, 18, 2013.
71. [71] Kiprijanovska, S., Davalieva, K., Noveski, P., Sukarova-Stefanovska, E., Plaseska-Karanfilska, D., Prevalence of hepatitis C virus genotypes in risk groups in the Republic of Macedonia: a 5 years survey. J Med Virol 85 (2013), 2072–2078.
72. [72] Shustov, A.V., Kochneva, G.V., Sivolobova, G.F., et al. Molecular epidemiology of the hepatitis C virus in Western Siberia. J Med Virol 77 (2005), 382–389.
73. [73] Seme, K., Vrhovac, M., Mocilnik, T., et al. Hepatitis C virus genotypes in 1,504 patients in Slovenia, 1993–2007. J Med Virol 81 (2009), 634–639.
74. [74] Matheï, C., Wollants, E., Verbeeck, J., et al. Molecular epidemiology of hepatitis C among drug users in Flanders, Belgium: association of genotype with clinical parameters and with sex- and drug-related risk behaviours. Eur J Clin Microbiol Infect Dis 24 (2005), 514–522.
75. [75] Krarup, H.B., Møller, J.M., Christensen, P.B., et al. Haemophilic patients with hepatitis C have higher viral load compared to other well-defined patient groups. J Viral Hepat 7 (2000), 435–439.
76. [76] Larsen, C., Bousquet, V., Delarocque-Astagneau, E., et al. Hepatitis C virus genotype 3 and the risk of severe liver disease in a large population of drug users in France. J Med Virol 82 (2010), 1647–1654.
77. [77] Schroter, M., Zollner, B., Laufs, R., Feucht, H.H., Changes in the prevalence of hepatitis C virus genotype among injection drug users: a highly dynamic process. J Infect Dis 190 (2004), 1199–1200 [Author reply 200-1].
78. [78] Elefsiniotis, I.S., Pantazis, K.D., Ketikoglou, I.D., Koutsounas, S.I., Tsianos, E.V., Changing serological status and low vaccination-induced protection rates against hepatitis B characterize chronic hepatitis C virus-infected injecting drug users in Greece: need for immunization policy. Eur J Gastroenterol Hepatol 18 (2006), 1227–1231.
79. [79] Löve, A., Sigurdsson, J.R., Stanzeit, B., Briem, H., Rikardsdottir, H., Widell, A., Characteristics of hepatitis C virus among intravenous drug users in Iceland. Am J Epidemiol 143 (1996), 631–636.
80. [80] Keating, S., Coughlan, S., Connell, J., Sweeney, B., Keenan, E., Hepatitis C viral clearance in an intravenous drug-using cohort in the Dublin area. Ir J Med Sci 174 (2005), 37–41.
81. [81] Stroffolini, T., D'Egidio, P.F., Aceti, A., et al. Hepatitis C virus infection among drug addicts in Italy. J Med Virol 84 (2012), 1608–1612.
82. [82] Grady, B.P., Prins, M., Rebers, S., Molenkamp, R., Geskus, R.B., Schinkel, J., BMI, male sex and IL28B genotype associated with persistently high hepatitis C virus RNA levels among chronically infected drug users up to 23 years following seroconversion. J Viral Hepat 22 (2015), 263–271.
83. [83] Calado, R.A., Rocha, M.R., Parreira, R., Piedade, J., Venenno, T., Esteves, A., Hepatitis C virus subtypes circulating among intravenous drug users in Lisbon, Portugal. J Med Virol 83 (2011), 608–615.
84. [84] Serra, M.A., Rodríguez, F., del Olmo, J.A., Escudero, A., Rodrigo, J.M., Influence of age and date of infection on distribution of hepatitis C virus genotypes and fibrosis stage. J Viral Hepat 10 (2003), 183–188.
85. [85] Lidman, C., Norden, L., Kåberg, M., et al. Hepatitis C infection among injection drug users in Stockholm Sweden: prevalence and gender. Scand J Infect Dis 41 (2009), 679–684.
86. [86] Senn, O., Seidenberg, A., Rosemann, T., Determinants of successful chronic hepatitis C case finding among patients receiving opioid maintenance treatment in a primary care setting. Addiction 104 (2009), 2033–2038.
87. [87] Hope, V.D., Hickman, M., Ngui, S.L., et al. Measuring the incidence, prevalence and genetic relatedness of hepatitis C infections among a community recruited sample of injecting drug users, using dried blood spots. J Viral Hepat 18 (2011), 262–270.
88. [88] Prasetyo, A.A., Dirgahayu, P., Sari, Y., Hudiyono, H., Kageyama, S., Molecular epidemiology of HIV, HBV, HCV, and HTLV-1/2 in drug abuser inmates in central Javan prisons, Indonesia. J Infect Dev Ctries 7 (2013), 453–467.
89. [89] Kageyama, S., Agdamag, D.M., Alesna, E.T., et al. Tracking the entry routes of hepatitis C virus as a surrogate of HIV in an HIV-low prevalence country, the Philippines. J Med Virol 81 (2009), 1157–1162.
90. [90] Yun, H., Kim, D., Kim, S., et al. High prevalence of HBV and HCV infection among intravenous drug users in Korea. J Med Virol 80 (2008), 1570–1575.
91. [91] Tanimoto, T., Nguyen, H.C., Ishizaki, A., et al. Multiple routes of hepatitis C virus transmission among injection drug users in Hai Phong, Northern Vietnam. J Med Virol 82 (2010), 1355–1363.
92. [92] Sanders-Buell, E., Rutvisuttinunt, W., Todd, C.S., et al. Hepatitis C genotype distribution and homology among geographically disparate injecting drug users in Afghanistan. J Med Virol 85 (2013), 1170–1179.
93. [93] Saha, K., Firdaus, R., Biswas, A., et al. Transmission dynamics of hepatitis C virus among intra venous drug users in the border state of Manipur, India. Infect Genet Evol 24 (2014), 57–67.
94. [94] Jamalidoust, M., Namayandeh, M., Asaei, S., Aliabadi, N., Ziyaeyan, M., Determining hepatitis C virus genotype distribution among high-risk groups in Iran using real-time PCR. World J Gastroenterol 20 (2014), 5897–5902.
95. [95] Shrestha, S.M., Shrestha, S., Tsuda, F., et al. Infection with GB virus C and hepatitis C virus in drug addicts, patients on maintenance hemodialysis, or with chronic liver disease in Nepal. J Med Virol 53 (1997), 157–161.
96. [96] ur Rehman, L., Ullah, I., Ali, I., et al. Active hepatitis C infection and HCV genotypes prevalent among the IDUs of Khyber Pakhtunkhwa. Virol J, 8, 2011, 327.
97. [97] Kurbanov, F., Tanaka, Y., Avazova, D., et al. Detection of hepatitis C virus natural recombinant RF1_2k/1b strain among intravenous drug users in Uzbekistan. Hepatol Res 38 (2008), 457–464.
98. [98] Sawada, L., Pinheiro, A.C., Locks, D., et al. Distribution of hepatitis C virus genotypes among different exposure categories in the State of Pará, Brazilian Amazon. Rev Soc Bras Med Trop 44 (2011), 8–12.
99. [99] Jacka, B., Applegate, T., Krajden, M., et al. Phylogenetic clustering of hepatitis C virus among people who inject drugs in Vancouver, Canada. Hepatology 60 (2014), 1571–1580.
100. [100] Uccellini, L., Tseng, F.C., Monaco, A., et al. HCV RNA levels in a multiethnic cohort of injection drug users: human genetic, viral and demographic associations. Hepatology 56 (2012), 86–94.
101. [101] Aitken, C.K., McCaw, R.F., Bowden, D.S., et al. Molecular epidemiology of hepatitis C virus in a social network of injection drug users. J Infect Dis 190 (2004), 1586–1595.
102. [102] Demetriou, V.L., van de Vijver, D.A., Hezka, J., Kostrikis, L.G., Network, C.I., Hepatitis C infection among intravenous drug users attending therapy programs in Cyprus. J Med Virol 82 (2010), 263–270.
103. [103] Mahfoud, Z., Kassak, K., Kreidieh, K., Shamra, S., Ramia, S., Distribution of hepatitis C virus genotypes among injecting drug users in Lebanon. Virol J, 7, 2010, 96.
104. [104] Alashek, W., Altagdi, M., Risk factors and genotypes of hepatitis C virus infection in libyan patients. Libyan J Med 3 (2008), 162–165.
105. [105] Trimbitas, R.D., Serghini, F.Z., Lazaar, F., et al. The “hidden” epidemic: a snapshot of Moroccan intravenous drug users. Virol J, 11, 2014, 43.
106. [106] Alzahrani, A.J., Dela Cruz, D.M., Obeid, O.E., Bukhari, H.A., Al-Qahtani, A.A., Al-Ahdal, M.N., Molecular detection of hepatitis B, hepatitis C, and torque teno viruses in drug users in Saudi Arabia. J Med Virol 81 (2009), 1343–1347.
107. [107] Muasya, T., Lore, W., Yano, K., et al. Prevalence of hepatitis C virus and its genotypes among a cohort of drug users in Kenya. East Afr Med J 85 (2008), 318–325.